Vical’s Vaxfectin(R) Adjuvant Drives 200-Fold Increase in Antibody Responses With Sanofi-Pasteur Fluzone(R) Seasonal Influenza Vaccine
Oct 27th, 2009 | By French BioBeach | Category: Latests News and AlertsVical’s Vaxfectin(R) Adjuvant Drives 200-Fold Increase in Antibody Responses
With Sanofi-Pasteur Fluzone(R) Seasonal Influenza Vaccine
Vical’s Vaxfectin(R) Adjuvant Drives 200-Fold Increase in Antibody Responses
With Sanofi-Pasteur Fluzone(R) Seasonal Influenza Vaccine
SAN DIEGO, Oct. 26, 2009 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL)
announced today the publication of two articles regarding the company’s
Vaxfectin(R) adjuvant in a special issue of Vaccine.(1,2) One article
highlighted [...]